Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock closed at 5.19 per share at the end of the most recent trading day (a -4.77% change compared to the prior day closing price) with a volume of 1.37M shares and market capitalization of 754.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 622 people. Adaptive Biotechnologies Corporation CEO is Chad Robins.

The one-year performance of Adaptive Biotechnologies Corporation stock is -28.41%, while year-to-date (YTD) performance is -32.07%. ADPT stock has a five-year performance of %. Its 52-week range is between 4.95 and 10.79, which gives ADPT stock a 52-week price range ratio of 4.54%

Adaptive Biotechnologies Corporation currently has a PE ratio of -5.30, a price-to-book (PB) ratio of 2.45, a price-to-sale (PS) ratio of 9.52, a price to cashflow ratio of 10.80, a PEG ratio of -, a ROA of -25.68%, a ROC of -32.78% and a ROE of -42.61%. The company’s profit margin is -93.01%, its EBITDA margin is -120.30%, and its revenue ttm is $130.11 Million , which makes it $0.91 revenue per share.

Of the last four earnings reports from Adaptive Biotechnologies Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Adaptive Biotechnologies Corporation’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Adaptive Biotechnologies Corporation is Strong Buy (1.29), with a target price of $13.6, which is +161.29% compared to the current price. The earnings rating for Adaptive Biotechnologies Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adaptive Biotechnologies Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adaptive Biotechnologies Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 18.87, ATR14 : 0.39, CCI20 : -80.67, Chaikin Money Flow : -0.35, MACD : -0.33, Money Flow Index : 33.65, ROC : -16.43, RSI : 36.06, STOCH (14,3) : 12.57, STOCH RSI : 0.49, UO : 35.91, Williams %R : -87.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adaptive Biotechnologies Corporation in the last 12-months were: Adams R. Mark (Sold 29 934 shares of value $257 082 ), Christopher Francis (Sold 6 816 shares of value $58 413 ), Elad Sharon (Sold 11 749 shares of value $100 689 ), Francis Lo (Sold 6 816 shares of value $58 413 ), Julie Rubinstein (Sold 22 668 shares of value $194 265 ), Kyle Piskel (Sold 4 795 shares of value $41 475 ), Nitin Sood (Sold 78 606 shares of value $638 533 ), Peterson Tycho (Sold 0 shares of value $-1 089 810 ), PETERSON TYCHO (Sold 242 961 shares of value $1 967 763 ), Piskel Kyle (Sold 3 529 shares of value $30 246 ), R Mark Adams (Sold 33 059 shares of value $279 767 ), Robert M. Hershberg (Option Excercise at a value of $23 850), Rubinstein Julie (Sold 22 668 shares of value $194 265 ), Sharon Benzeno (Sold 11 749 shares of value $100 689 ), Sood Nitin (Sold 32 676 shares of value $248 794 ), Stacy L. Taylor (Sold 18 878 shares of value $162 186 ), Taylor Stacy (Sold 18 878 shares of value $162 186 )